Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
Browsing: Uncategorized
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
Bioniche Life Sciences has received its first milestone payment of $6 million from Endo Pharmaceuticals for its experimental bladder cancer drug.